Skip to content
DataLookout
Menu

SPRINGNCT04480853

Safety and Efficacy Study of Fingolimod in Taiwanese Adults (≥ 20years) With Relapsing Remitting Multiple Sclerosis

StatusActive, Not Recruiting
PhasePhase 4
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 19 versions: 14 with changes below, 5 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Minor Enrollment closed, study ongoing Show 5 more changesShow less
    • Trial sites reduced: 6 → 3 locations
    • Final enrollment: 14 participants (planned 30)
    • Primary completion date changed from estimate of Sep 30, 2027 to Oct 15, 2026
    • Eligibility criteria expanded, about 10 words
    • Secondary endpoints: details revised at 3 of 3 entries
  2. Minor Site details revised at 1 of 6 sitesv15
  3. Notable Primary and study completion dates: Jan 27, 2026 to Sep 30, 2027
    • Site details revised at 2 of 6 sites
    v14
  4. Minor Site details revised at 2 of 6 sitesv12
  5. Notable Primary and study completion dates: Feb 28, 2025 to Jan 27, 2026v11
Show 8 earlier versionsHide 8 earlier versions
  1. Minor Site details revised at 1 of 6 sitesv10
  2. Notable Primary and study completion dates pushed to Feb 28, 2025
    • Study sites: 5 to 6
    v9
  3. Notable Primary completion date: Jul 15, 2022 to Jul 15, 2024
    • Study completion date: Jul 15, 2022 to Oct 15, 2024
    v8
  4. Minor Study sites: 4 to 5v6
  5. Minor Study sites: 1 to 4v5
  6. Notable Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    v4
  7. Minor Start date: Sep 15, 2020 to Oct 12, 2020v3
  8. Notable Start date: Aug 14, 2020 to Sep 15, 2020
    • Eligibility criteria revised
    v2
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Number of Adverse Events of Special Interest(AESI)
Timeframe: First Dose Observation on the first day of taking findolimod
Number of Adverse Events of Special Interest (AESI)
Timeframe: Baseline up to 12 months

Secondary (3)

Annualized relapse reate (ARR)
Change from baseline of Pulse (beats/min)
Change from baseline of blood pressure (mmHg)

Arms and interventions

FingolimodExperimental

Open label Fingolimod 0.5 mg capsule taken once daily, oral.

Drugs: Fingolimod

Sites

3 sites in 1 country